L2M QC 2024 – “Brave Technologies : A new breast cancer diagnostic device”

Breast cancer remains a major global health concern, with high prevalence rates in new case diagnoses across the world. The primary challenge in breast cancer detection centers on achieving early and precise diagnosis as actual methods have limitations. The primary challenge in breast cancer detection lies in achieving early and accurate diagnosis. Current methods face significant limitations, including difficulties in accommodating the variability in tumor characteristics such as size, shape, and location. Our system offers substantial opportunities to address these issues effectively by providing a non-invasive, patient-friendly, and precise detection method, particularly advantageous for women with dense breast tissue. By introducing our device to the market and building trust with customers, we will be able to detect breast cancer at early stages, providing patients with a better chance to fight and overcome this disease, thereby contributing to reducing mortality rates caused by breast cancer. The main objective of this project is for the intern to conduct an in-depth market study in the Final Users, private sector, and non-profit entities segments for the potential applications of the BRAVE System, an innovative, accessible, and affordable breast cancer detection method specifically designed for women with dense breast tissue

Faculty Supervisor:

Elijah Van Houten;Valérie Grandbois

Student:

Partner:

V1 Studio

Discipline:

Engineering

Sector:

Health and Related Sciences & Technology

University:

Université de Sherbrooke

Program: